The University of Chicago Header Logo

Connection

James Dignam to Ipilimumab

Back to Details
This is a "connection" page, showing publications James Dignam has written about Ipilimumab.
James Dignam
Connection Strength
0.057
Ipilimumab
  1. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20; 43(27):3032-3040.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.